Back to News
Market Impact: 0.1
Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of TJ102, an FRα × CDH6 Bispecific Dual-Payload ADC
Source: PR Newswire
Healthcare & BiotechTechnology & Innovation
Phrontline Biopharma announced the first clinical program built on its DLP1 branched dual-payload linker platform for next-generation antibody-drug conjugates. The provided excerpt does not identify the candidate, trial stage, clinical data, financial terms, or development timeline, limiting the immediate investment significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Tencent leases 100,000 chips from Oracle for $7 bln- FT
- California Gov. Gavin Newsom bans AI 'robo bosses' in landmark state law, reversing his earlier veto
- RAM supply set to worsen, says Micron, as CEO celebrates ‘much higher’ prices
- Why is Kioxia stock rallying today?
- We're raising our Micron price target after an incredible quarter and robust guidance
- Micron Forecast Tops Estimates on Booming AI Memory Demand